US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

42.72

+1.072.57%

Post-market: 42.970.2500+0.59%19:59 EDT

Volume:219.40K

Turnover:9.26M

Market Cap:318.26M

PE:- -

High:42.86

Open:41.64

Low:41.44

Close:41.65

52wk High:42.97

52wk Low:23.90

Shares:7.45M

Float Shares:7.45M

Volume Ratio:0.69

T/O Rate:2.94%

Dividend:0.28

Dividend Rate:0.65%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

Forge Nano and Nanexa to Develop Gmp-Compatible Ald Manufacturing Equipment

Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial

MT Newswires Live

Incyte Posts 24-Week TRuE-AD4 Data on Long-Term Safety of Ruxolitinib Cream in Moderate Atopic Dermatitis at EADV 2026

Nanexa, Forge Nano Enter Joint Development Deal on GMP-Scale ALD Equipment for PharmaShell Injectables

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria

Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria

THOMSON REUTERS

Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts

THOMSON REUTERS

Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial

THOMSON REUTERS

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology

Roche says Phase II obesity study met both primary endpoints

Moderna Inc. Stock Climbs 12.3%, Outperforms Peers

Moderna Provides Details on Data Presentations at Upcoming Conferences

MT Newswires Live

Twist Bioscience CEO Emily M. Leproust Disposes of USD 51.47 Million in Common Shares

Why Is Moderna Stock (MRNA) Soaring Today, September 21?

Moderna Inc Stock (MRNA) Moved Up by 14.21% on Sep 21: Drivers Behind the Movement

Moderna Stock Jumps. Its mRNA Cancer Vaccine is Getting Ready for Its Next Big Test.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/IDNA/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":42.72,"timestamp":1791230400000,"preClose":41.65,"halted":0,"volume":219396,"hourTrading":{"tag":"盘后","latestPrice":42.97,"preClose":42.72,"latestTime":"19:59 EDT","volume":2505,"amount":107179.02,"timestamp":1791244769975,"change":0.25,"changeRate":0.005852,"amplitude":0.005852},"delay":0,"changeRate":0.025690276110444187,"floatShares":7450000,"shares":7450000,"eps":0,"marketStatus":"Closed","change":1.07,"latestTime":"10-05 16:00:00 EDT","open":41.64,"high":42.855,"low":41.44,"amount":9262746.200987998,"amplitude":0.033974,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791273600000},"marketStatusCode":5,"adr":0,"exchange":"ARCA","adjPreClose":41.65,"sharesOutstanding":5100000,"nav":41.483661,"aum":309297448.94,"dividendRate":0.006538,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":42.28,"preClose":41.65,"latestTime":"08:46 EDT","volume":75,"amount":3191.99985,"timestamp":1791204366525,"change":0.63,"changeRate":0.015126,"amplitude":0.020168},"postHourTrading":{"tag":"盘后","latestPrice":42.97,"preClose":42.72,"latestTime":"19:59 EDT","volume":2505,"amount":107179.02,"timestamp":1791244769975,"change":0.25,"changeRate":0.005852,"amplitude":0.005852},"volumeRatio":0.685928,"impliedVol":0.2456,"impliedVolPercentile":0.6932},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":7450000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.685928,"shares":7450000,"dividePrice":0.2793,"high":42.855,"amplitude":0.033974,"preClose":41.65,"low":41.44,"week52Low":23.9,"pbRate":"--","week52High":42.97,"institutionHeld":0,"latestPrice":42.72,"eps":0,"divideRate":0.006538,"volume":219396,"delay":0,"ttmEps":0,"open":41.64,"prevYearClose":26.19,"prevWeekClose":41.65,"prevMonthClose":42.32,"prevQuarterClose":42.32,"fiveDayClose":41.79,"twentyDayClose":39.77,"sixtyDayClose":33.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669142210","title":"AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142210","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142210?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:55","pubTimestamp":1790081700,"startTime":"0","endTime":"0","summary":"Daraxonrasib is an important therapeutic advance, but pancreatic cancer is not a simple disease where one successful targeted drug makes additional therapeutic development unnecessary. We believe Ampligen has the potential to complement and extend therapies such as daraxonrasib by helping to overcome the immune biological barriers that have h","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/22/3366375/29489/en/aim-immunotech-highlights-ampligen-s-potential-role-in-the-evolving-pancreatic-cancer-treatment-landscape-following-fda-approval-of-revolution-medicines-daraxonrasib.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BBH","IE00BJJMRZ35.SGD","BK4588","LU0320765992.SGD","BK4585","IE0002141913.USD","IDNA","LU0109394709.USD","IE0009355771.USD","RVMD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","IE0009354923.USD","CANC","LABU","BK4139","PTH","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142551","title":"Forge Nano and Nanexa to Develop Gmp-Compatible Ald Manufacturing Equipment","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142551","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142551?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:52","pubTimestamp":1790081527,"startTime":"0","endTime":"0","summary":"Sept 22 (Reuters) - Nanexa AB::*FORGE NANO AND NANEXA TO DEVELOP GMP-COMPATIBLE ALD MANUFACTURING EQUIPMENT FOR PHARMASHELL PORTFOLIO*PORTFOLIO INCLUDES LICENSE AGREEMENT WITH MODERNA AND UNDISCLOSED ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nRSD6607P3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4548","GNOM","MRNY","BK4568","LGHT","BK4585","BK4533","BK4534","BK4551","BK4588","WDNA","MRNX","MRNA","BK4501","IDNA","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669425861","title":"Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669425861","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669425861?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:50","pubTimestamp":1790081406,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals  said Tuesday that a phase 2b study of inaxaplin to treat patients with APOL1-mediated kidney disease showed a 42.7% protein reduction, and a 17.3% reduction in patients who also have type 2 diabetes.The company said the drug showed a favorable safety profile with no drug-related serious adverse events reported. It said headaches were the most frequent side effect, which affected 7.3% of trial participants.The company said the reduction was measured after 13 weeks of treatment. Vertex said it has finished enrolling patients in a larger Phase 2/3 trial of inaxaplin.Shares of Vertex were up 2.2% pre-bell.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4533","IBB","IE00B894F039.SGD","IE00BZ9MQY76.HKD","LU1093756325.SGD","LU1815336091.USD","IE00B19Z9Z06.USD","LU1778281490.HKD","LU2362540622.SGD","SG9999013999.USD","LU1674673428.USD","IE00B19Z9P08.USD","LU1559883803.SGD","LU1674673691.USD","LU2362541513.USD","TBXU","LU2417539215.USD","LU0566484027.USD","IE00BJJMRZ35.SGD","BK4023","IE0002141913.USD","PBE","IE00BJT1NW94.SGD","LU2236285917.USD","LU1069344957.HKD","IE0002270589.USD","LU2468319806.SGD","LU0061475181.USD","IE0009355771.USD","BK4139","IE00B19Z3581.USD","BK4532","LU0757428866.USD","BIB","VRTX","LU2324357040.USD","SG9999001176.USD","LU0079474960.USD","IDNA","SGXZ57979304.SGD","VERX","LU0058720904.USD","BBH","BK4588","LU1035775433.USD","GNMX","SG9999001176.SGD","BK4567","LU2089984988.USD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144123","title":"Incyte Posts 24-Week TRuE-AD4 Data on Long-Term Safety of Ruxolitinib Cream in Moderate Atopic Dermatitis at EADV 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144123","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144123?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:32","pubTimestamp":1790080377,"startTime":"0","endTime":"0","summary":"Incyte posts 24-week TRuE-AD4 data on long-term safety of ruxolitinib cream in moderate atopic dermatitis at EADV 2026Incyte flagged new clinical and real-world data across its inflammation and autoim","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL7N04HG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","BK4532","BK4588","INCY","BK4585","BK4550","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669125144","title":"Nanexa, Forge Nano Enter Joint Development Deal on GMP-Scale ALD Equipment for PharmaShell Injectables","url":"https://stock-news.laohu8.com/highlight/detail?id=2669125144","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669125144?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:32","pubTimestamp":1790080347,"startTime":"0","endTime":"0","summary":"Nanexa, Forge Nano enter joint development deal on GMP-scale ALD equipment for PharmaShell injectablesNanexa entered a joint development agreement with Forge Nano to scale atomic layer deposition manu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL1PQdFL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNOM","WDNA","BK4588","IDNA","BK4568","BK4548","BK4585","MRNA","BK4139","BK4501","BK4532","MRNY","BK4534","LGHT","BK4551","MRNX","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144047","title":"Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144047","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144047?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:30","pubTimestamp":1790080200,"startTime":"0","endTime":"0","summary":"New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca’s Phase 1 ERAS-0015 Datase","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/22/3366329/0/en/propanc-biopharma-highlights-differentiated-prp-pancreatic-cancer-data-versus-emerging-pan-ras-program-eras-0015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0724618433.USD","LU1861220033.SGD","BK4548","BBH","01698","BK4141","BK4571","PDX","BK4585","LU0109394709.USD","LU0269904917.USD","BK4535","IE00BYTNYN87.SGD","LU0359202008.SGD","LU1861219969.SGD","BK4139","BK4509","LU1548497426.USD","IE00B12V2V27.USD","LU1720051017.SGD","BK4108","BK4588","ONG","LU1023057109.AUD","PPCB","SG9999011746.SGD","CANC","BK4531","IE00BJT1NW94.SGD","LU1854103824.USD","LU1854104046.USD","BK4512","TME","PTH","ONX","BK4565","IDNA","RVMD","ERAS","IE0009354923.USD","LU0320765992.SGD","LU0509642566.USD","BK4605","LU2357305700.SGD","ON","LU2360107325.USD","LU2298322129.HKD","IE00BFTCPJ56.SGD","IE00BYQNZ168.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144313","title":"Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144313","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144313?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:15","pubTimestamp":1790079331,"startTime":"0","endTime":"0","summary":"The company states: “Vertex Pharmaceuticals (VRTX) announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-positive-results-from-phase-2b-inaxaplin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-positive-results-from-phase-2b-inaxaplin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1430594728.SGD","IE00B19Z3B42.SGD","IE00B19Z9Z06.USD","LU0432979614.USD","IE0009355771.USD","LU0109394709.USD","LU0061475181.USD","LU2362540622.SGD","LU2462157665.USD","TBXU","BK4567","LU1093756325.SGD","LU0320765992.SGD","LU2236285917.USD","LU2237438978.USD","LU1093756168.USD","IBBQ","LU1585245621.USD","LU0289739699.SGD","IDNA","IE00B2B36J28.USD","VERX","GNMX","LU0823416689.USD","IE0002141913.USD","BK4023","LU0757428866.USD","BK4139","LU1674673428.USD","BIB","LU0234570918.USD","IE00B19Z3581.USD","IE00B4R5TH58.HKD","BK4532","IE00BFTCPJ56.SGD","LU1035775433.USD","LU1674673691.USD","IBB","LU1815336091.USD","SG9999001176.SGD","BBH","IE00BJT1NW94.SGD","LU0256863811.USD","BK4588","VRTX","LU1778281490.HKD","PBE","LU2089984988.USD","SG9999013999.USD","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669440251","title":"IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2669440251","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669440251?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:05","pubTimestamp":1790078700,"startTime":"0","endTime":"0","summary":"Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date No cytokine release syndrome, systemic toxi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/22/3366307/0/en/imunon-reports-independent-data-monitoring-committee-recommends-continued-phase-2-development-of-imnn-001-following-favorable-safety-review.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","IDNA","IMNN","BK4139","BK4211","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669177141","title":"Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669177141","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669177141?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:02","pubTimestamp":1790078577,"startTime":"0","endTime":"0","summary":"Vertex says Phase 2b AMPLIFIED study shows inaxaplin cuts proteinuria in APOL1-mediated kidney disease patients with modest proteinuriaVertex reported positive Phase 2b AMPLIFIED results for inaxaplin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL8CHhBr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","IBBQ","TBXU","IE00B19Z9P08.USD","LU0889565916.HKD","LU0823416689.USD","IE0002141913.USD","BK4532","PBE","LU0320765992.SGD","IE00BJT1NW94.SGD","IDNA","VRTX","BBH","LU1674673428.USD","BK4567","LU2462157665.USD","LU0061475181.USD","LU0109394709.USD","LU1035775433.USD","LU1069344957.HKD","LU2362541513.USD","IE00B2B36J28.USD","LU1093756325.SGD","LU0058720904.USD","LU0256863811.USD","IBB","BK4585","LU0079474960.USD","LU2089984988.USD","LU2468319806.SGD","IE00B19Z3581.USD","BIB","LU0432979614.USD","LU1093756168.USD","BK4588","SG9999013999.USD","IE00BFTCPJ56.SGD","LU1674673691.USD","BK4139","IE0002270589.USD","IE00B19Z9Z06.USD","GNMX","SG9999001176.SGD","LU2237438978.USD","SGXZ57979304.SGD","IE0009355771.USD","LU2362541273.HKD","IE00BZ9MQY76.HKD","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669419861","title":"Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669419861","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669419861?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2324357040.USD","LU0234570918.USD","LU0109394709.USD","BK4139","IE00B2B36J28.USD","LU2236285917.USD","BK4585","LU1430594728.SGD","IE00B4R5TH58.HKD","LU1069344957.HKD","SG9999001176.SGD","LU0079474960.USD","LU2362540622.SGD","IDNA","IE0002141913.USD","LU0256863811.USD","LU2468319806.SGD","IE00B19Z9P08.USD","TBXU","LU1778281490.HKD","LU2456880835.USD","IE0002270589.USD","LU1093756325.SGD","LU2462157665.USD","LU0417517546.SGD","LU2417539215.USD","SGXZ57979304.SGD","BIB","IBB","IE00BJT1NW94.SGD","IE00B894F039.SGD","LU0823416689.USD","IE00B19Z9Z06.USD","IBBQ","LU1674673691.USD","IE0009355771.USD","LU0289739699.SGD","GNMX","LU2237438978.USD","VRTX","LU2362541273.HKD","LU1585245621.USD","LU1674673428.USD","LU0889565916.HKD","LU2362541513.USD","PBE","IE00B19Z3581.USD","LU1093756168.USD","IE00BJJMRZ35.SGD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669419041","title":"Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts","url":"https://stock-news.laohu8.com/highlight/detail?id=2669419041","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669419041?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B4R5TH58.HKD","LU0432979614.USD","IE00BZ9MQY76.HKD","SG9999001176.SGD","LU0256863811.USD","VRTX","LU0889565916.HKD","LU2362541273.HKD","LU1035775433.USD","LU1069344957.HKD","BBH","BK4139","LU0320765992.SGD","LU1674673428.USD","PBE","LU0058720904.USD","BK4532","IE00BJJMRZ35.SGD","SG9999013999.USD","BK4567","LU0234570918.USD","IE00B19Z9P08.USD","LU2089984988.USD","BIB","IE00B19Z9Z06.USD","IE00BJT1NW94.SGD","LU0061475181.USD","SGXZ57979304.SGD","LU2324357040.USD","IE0002141913.USD","LU0079474960.USD","BK4533","IBB","LU2362541513.USD","TBXU","IBBQ","IE0002270589.USD","LU1778281490.HKD","IDNA","BK4588","GNMX","LU2456880835.USD","BK4585","SG9999001176.USD","LU0109394709.USD","LU1585245621.USD","LU2417539215.USD","LU1093756325.SGD","LU2237438978.USD","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669141954","title":"Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669141954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669141954?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999001176.SGD","IBBQ","IE00B19Z3581.USD","BK4532","LU1778281490.HKD","IE00BJT1NW94.SGD","LU0417517546.SGD","BK4585","LU1035775433.USD","LU1069344957.HKD","LU0058720904.USD","LU0432979614.USD","LU0061475181.USD","SGXZ57979304.SGD","SG9999001176.USD","LU1674673428.USD","LU0234570918.USD","LU0256863811.USD","BK4139","IE00BZ9MQY76.HKD","BK4533","LU0823416689.USD","LU2456880835.USD","SG9999013999.USD","LU1093756325.SGD","BBH","IE00B19Z3B42.SGD","TBXU","VRTX","LU1585245621.USD","LU0889565916.HKD","IE0002270589.USD","LU0320765992.SGD","PBE","LU0079474960.USD","IE0002141913.USD","GNMX","BIB","IE00B19Z9P08.USD","LU0109394709.USD","IBB","BK4567","LU1674673691.USD","LU2237438978.USD","LU0289739699.SGD","LU2089984988.USD","LU2236285917.USD","IE00B4R5TH58.HKD","IDNA","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669882142","title":"PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2669882142","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669882142?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078400,"startTime":"0","endTime":"0","summary":"39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor nave patients Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partn","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/22/3366230/37149/en/pds-biotech-announces-publication-of-versatile-002-phase-2-clinical-trial-results-of-pds0101-with-pembrolizumab-in-hpv16-positive-recurrent-and-or-metastatic-r-m-head-and-neck-canc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","IDNA","BK4581","BK4588","BK4585","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669414868","title":"Roche says Phase II obesity study met both primary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2669414868","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669414868?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:20","pubTimestamp":1790068829,"startTime":"0","endTime":"0","summary":"Roch announced topline results from CT-388-104, a Phase II clinical trial evaluating enicepatide, an investigational, once-weekly dual GLP-1/GIP re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-says-phase-ii-obesity-study-met-both-primary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-says-phase-ii-obesity-study-met-both-primary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","HYLG","JDOC","GDOC","MEDX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669619383","title":"Moderna Inc. Stock Climbs 12.3%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2669619383","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669619383?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:33","pubTimestamp":1790022780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. jumped 12.3% to $172.94 on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 2.3% to 27,122.09 and the Dow Jones Industrial Average rising 0.7% to 52,048.83.Moderna Inc. closed 2.1% short of its 52-week high of $176.66, which the company reached on August 19th.The stock outperformed some of its peers, as Johnson & Johnson fell 0.2% to $269.47, Pfizer Inc. rose 0.3% to $27.74, and Gilead Sciences Inc. rose 0.30% to $150.56.Trading volume totaled 20.9 million, compared to the 50-day average of 17.9 million.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","LU1023059063.AUD","LU1430594728.SGD","LU0058720904.USD","LGHT","LU2468319806.SGD","BK4533","BK4578","IBBQ","LU2089984988.USD","TMED","GILD","BK4534","BIB","MEDI","LU0861579265.USD","BK4501","LU0234570918.USD","LU1674673428.USD","LU1066053197.SGD","SG9999015986.USD","MRNX","LU0965509101.SGD","MRNY","BK4532","IE00BSNM7G36.USD","WDNA","LU1778281490.HKD","LU1061106388.HKD","LU0289739699.SGD","MRNA","BBH","BK4548","LU0122379950.USD","TBXU","LU0859254822.USD","IBB","LU0109394709.USD","IE0002270589.USD","LU0889565916.HKD","BK4139","LU1839511570.USD","LU1066051498.USD","LU0882574055.USD","IDNA","LU1934455194.USD","GNOM","SG9999015952.SGD","IE00B7SZLL34.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669619810","title":"Moderna Provides Details on Data Presentations at Upcoming Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2669619810","media":"MT Newswires Live","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669619810?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:13","pubTimestamp":1790021603,"startTime":"0","endTime":"0","summary":"Moderna  said Monday that phase 3 data for intismeran autogene in resected stage IIB-IV melanoma will be presented at a Presidential Symposium during the ESMO Congress 2026 on Oct. 24.The company said three abstracts on the investigational individualized neoantigen therapy were accepted for presentation, including data from a phase 1 pancreatic cancer study and a phase 3 lung cancer study.The company will also present in the Bernstein Insights Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum on Sept. 23, according to its website.Price: 173.39, Change: +19.35, Percent Change: +12.56","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4551","BK4533","WDNA","BK4532","MRNX","BK4548","GNOM","MRNA","BK4139","BK4585","IDNA","BK4534","LGHT","BK4588","MRNY","BK4501","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669119897","title":"Twist Bioscience CEO Emily M. Leproust Disposes of USD 51.47 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2669119897","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669119897?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:06","pubTimestamp":1790021163,"startTime":"0","endTime":"0","summary":"Twist Bioscience CEO Emily M. Leproust disposes of USD 51.47 million in common sharesTwist Bioscience CEO Emily M. Leproust exercised employee stock options for 208,708 shares on Sept. 17, 2026.She so","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL6bV88H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Twist Bioscience CEO Emily M. Leproust Disposes of USD 51.47 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","ARKG","IDNA","BK4139","WDNA","GNOM","BK4588","TWST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669160402","title":"Why Is Moderna Stock (MRNA) Soaring Today, September 21?","url":"https://stock-news.laohu8.com/highlight/detail?id=2669160402","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669160402?lang=en_us&edition=fundamental","pubTime":"2026-09-22 02:54","pubTimestamp":1790016874,"startTime":"0","endTime":"0","summary":"Moderna shares ($MRNA) surged by more than 14% to about $176 on Monday afternoon. This came after the U.S. pharma and biotech firm announced a key ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-moderna-stock-mrna-soaring-today-september-12?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-moderna-stock-mrna-soaring-today-september-12?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4501","WDNA","BK4585","MRNX","BK4534","IDNA","GNOM","BK4532","BK4548","MRNA","BK4568","BK4551","XBIX","LGHT","BK4139","BK4533","BK4588","MRNY","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669316058","title":"Moderna Inc Stock (MRNA) Moved Up by 14.21% on Sep 21: Drivers Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2669316058","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669316058?lang=en_us&edition=fundamental","pubTime":"2026-09-22 02:15","pubTimestamp":1790014526,"startTime":"0","endTime":"0","summary":"• Moderna stock rose due to positive Phase 3 oncology trial results and upcoming congress presentations.\n• FDA approval of updated COVID-19 vaccines and capital-raising initiatives reinforced institutional financial confidence.\n• Moderna reported annual revenue of $1.94 billion and a net loss of $2.82 billion.","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262178943-market-movers-mrna-20260921","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","MRNY","BK4585","BK4568","LGHT","BK4551","BK4534","IDNA","MRNA","BK4532","GNOM","BK4139","BK4548","BK4501","BK4533","MRNX","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669528167","title":"Moderna Stock Jumps. Its mRNA Cancer Vaccine is Getting Ready for Its Next Big Test.","url":"https://stock-news.laohu8.com/highlight/detail?id=2669528167","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669528167?lang=en_us&edition=fundamental","pubTime":"2026-09-22 01:12","pubTimestamp":1790010720,"startTime":"0","endTime":"0","summary":"Moderna stock nearly tripled in a single day last month after the drugmaker proved a personalized cancer vaccine is no longer just theoretical. Investors are about to find out what's next.The drugmake","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4501","BK4588","GNOM","MRNY","BK4139","BNTX","BK4535","WDNA","LGHT","BK4585","BK4533","BK4568","BK4551","MRNX","BK4534","MRNA","BK4532","BK4548","IDNA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}